CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-04-11 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Option exercise 10b5-1 | +30,000 | $1.12 | $34K | 30,000 |
| 2024-04-11 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −30,000 | $25.04 | $751K | 0 |
| 2024-04-11 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −30,000 | 230,550 | ||
| 2024-04-11 | Kintz Samuel PRESIDENT AND CEO | Option exercise 10b5-1 | +47,709 | $1.12 | $53K | 47,709 |
| 2024-04-11 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −47,709 | $25.04 | $1.2M | 0 |
| 2024-04-11 | Kintz Samuel PRESIDENT AND CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −47,709 | 212,841 | ||
| 2024-04-11 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +14,000 | $2.48 | $35K | 14,000 |
| 2024-04-11 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −3,777 | $23.88 | $90K | 10,223 |
| 2024-04-11 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −10,223 | $25.04 | $256K | 0 |
| 2024-04-11 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −14,000 | 225,370 | ||
| 2024-04-11 | Heyman Richard A. Director | Sale 10b5-1 | −5,045 | $25.03 | $126K | 138.43 |
| 2024-04-11 | Heyman Richard A. Director | Sale 10b5-1 | −649 | $25.00 | $16K | 28,567 |
| 2024-04-11 | Collins Helen Louise CHIEF MEDICAL OFFICER | Option exercise 10b5-1 | +20,000 | $2.48 | $50K | 20,000 |
| 2024-04-11 | Collins Helen Louise CHIEF MEDICAL OFFICER | Sale 10b5-1 | −20,000 | $25.07 | $501K | 0 |
| 2024-04-11 | Collins Helen Louise CHIEF MEDICAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −20,000 | 267,084 | ||
| 2024-04-11 | Ballal Rahul D. Director | Option exercise 10b5-1 | +48,820 | $12.60 | $615K | 71,161 |
| 2024-04-11 | Ballal Rahul D. Director | Option exercise 10b5-1 | +4,580 | $19.68 | $90K | 75,741 |
| 2024-04-11 | Ballal Rahul D. Director | Sale 10b5-1 | −30,300 | $23.14 | $701K | 45,441 |
| 2024-04-11 | Ballal Rahul D. Director | Sale 10b5-1 | −20,032 | $25.00 | $501K | 25,409 |
| 2024-04-11 | Ballal Rahul D. Director | Sale 10b5-1 | −3,068 | $25.21 | $77K | 22,341 |
Page 22 of 37 · 724 trades